Apellis Pharmaceuticals Inc [APLS] stock prices are up 0.40% to $25.14 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APLS shares have gain 4.49% over the last week, with a monthly amount drifted -16.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on December 17, 2024, when Goldman downgraded its rating to a Neutral but kept the price target unchanged to $36 for it. Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on November 21, 2024, and set its price target to $31. On October 25, 2024, RBC Capital Mkts initiated with a Sector Perform rating and assigned a price target of $25 on the stock. William Blair started tracking the stock assigning a Outperform rating. Scotiabank initiated its recommendation with a Sector Outperform. Piper Sandler started tracking with a Neutral rating for this stock on May 31, 2024, and assigned it a price target of $46. In a note dated February 05, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $68 to $80.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $23.77 and $63.40 over the past year. Currently, Wall Street analysts expect the stock to reach $68 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $25.14 at the most recent close of the market. An investor can expect a potential return of 170.49% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 781.37M for trailing twelve months, representing a surge of 45.19%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.21%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.79 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.60 points at the first support level, and at 24.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.56, and for the 2nd resistance point, it is at 25.98.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 4.25. Further, the Quick Ratio stands at 3.81, while the Cash Ratio is 2.22. Considering the valuation of this stock, the price to sales ratio is 4.04, the price to book ratio is 13.69.
Transactions by insiders
Recent insider trading involved Watson David O., General Counsel, that happened on Mar 05 ’25 when 5569.0 shares were sold. Officer, DAVID OSBORNE WATSON completed a deal on Mar 05 ’25 to buy 5569.0 shares. Meanwhile, Chief Business & Strat Officer DeLong Mark Jeffrey sold 363.0 shares on Feb 11 ’25.
